Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Arbutus和Barinthus Bio宣佈，在Im-Prove II試驗中獲得的新數據顯示，加入nivolumab後，慢性乙型肝炎患者的Hbsag丟失率有所增加。
